Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)

Fungal Infection Clinical Trial

Official title:

A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00811642
• Other study ID #: P05551
• Status: Completed
• Phase: Phase 3
• First received: December 18, 2008
• Last updated: June 4, 2015
• Start date: November 2008
• Est. completion date: March 2010

Study information

• Verified date: June 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Participants must be 18-70 years male or female

• Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.

• Sign informed consent form

Exclusion Criteria:

• Female participants who are pregnant or are nursing.

• Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B

• Participants with progressive nervous system diseases( excluding those IFI caused)

• Participants who take the following drugs known with interference with azole antifungal preparations

• terfenadine, cisapride, and ebastine within 24 hours before entry

• astemizole at entry or within 10 days before entry

• cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry

• The drugs listed above are prohibited during the investigation

• Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate <60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.

• Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.

• Expected to take during investigation or is taking systemic antifungal treatment

• Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are >2×ULN.

• Participants expected to survive no more than 72hrs

• Participants receiving artificial aeration and will not withdraw within 24hrs

• Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.

• Prior enrollment in this study.

• History of alcohol and/or drug abuse.

• Participants cannot be compliant in investigator's opinion.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Communicable Diseases
• Fungal Infection
• Infection
• Mycoses

Intervention

Drug:
• Posaconazole
400mg BID oral suspension for 12 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Huang X, Wang F, Chen Y, Liu T, Wang J, Hu J, Jie J, Chen F, Wang S, Shen Z, Yu L, Yu K, Liang Y. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of fir — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment	EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of Invasive Fungal Infection (IFI) attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.; Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.; Stable disease: no progress in IFI attributable symptoms, if present at enrollment.; Failure: deterioration in IFI attributable clinical symptoms.	Treatment week 12	No
Secondary	Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment	EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.; Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.; Stable disease: no progress in IFI attributable symptoms, if present at enrollment.; Failure: deterioration in IFI attributable clinical symptoms.	Treatment week 4	No
Secondary	Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment	EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA: Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.; Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.; Stable disease: no progress in IFI attributable symptoms, if present at enrollment.; Failure: deterioration in IFI attributable clinical symptoms.	Treatment week 8	No
Secondary	Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment	EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting; fungal pathogen from a primary site previously positive.; Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.; Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.	Treatment week 4	No
Secondary	Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment	EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting; fungal pathogen from a primary site previously positive.; Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.; Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.	Treatment week 8	No
Secondary	Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment	EVALUATION OF FUNGAL ERADICATION: Participants' mycological response to therapy was assessed by the following: Eradication: Negative culture or histologically documented absence of infecting; fungal pathogen from a primary site previously positive.; Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.; Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.	Treatment week 12	No
Secondary	Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up	Total number of participant deaths was assessed at the end of 2 week post-treatment follow-up (14 weeks). The total number of deaths was compared to the number of survivors at baseline.	Follow-up week 14	No